BioSight
Companies
Immunocore Holdings plc logo

IMCR

NASDAQOXFORDSHIRE, X0
Immunocore Holdings plc

Immunocore Holdings plc develops immunotherapies using its ImmTAX platform technology to treat cancer and other diseases. The company has one approved product, KIMMTRAK, for metastatic uveal melanoma, and is expanding it into additional melanoma indications and other tumor types, while building a pipeline of earlier-stage programs across oncology and beyond. Immunocore is in the commercialization phase with KIMMTRAK while simultaneously advancing multiple clinical-stage candidates through development.

Price history not yet available for IMCR.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar